Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor
Blood Adv
.
2023 Sep 26;7(18):5210-5214.
doi: 10.1182/bloodadvances.2023010407.
Authors
Zachary D Crees
1
,
Michael P Rettig
1
,
Asad Bashey
2
,
Steven M Devine
3
,
Samantha Jaglowski
4
,
Fei Wan
1
,
Amy Zhou
1
,
Melinda Harding
1
,
Abi Vainstein-Haras
5
,
Ella Sorani
5
,
Irit Gliko-Kabir
5
,
Brenda J Grossman
6
,
Peter Westervelt
1
,
John F DiPersio
1
,
Geoffrey L Uy
1
Affiliations
1
Division of Oncology, Washington University School of Medicine, St. Louis, MO.
2
Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA.
3
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program, Minneapolis, MN.
4
Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
5
BioLineRx Ltd, Modi'in, Israel.
6
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO.
PMID:
37327120
PMCID:
PMC10500469
DOI:
10.1182/bloodadvances.2023010407
No abstract available
Publication types
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Letter
MeSH terms
Hematopoietic Stem Cell Mobilization
Hematopoietic Stem Cell Transplantation*
Peripheral Blood Stem Cell Transplantation*
Grants and funding
P30 CA091842/CA/NCI NIH HHS/United States
R35 CA210084/CA/NCI NIH HHS/United States
R50 CA211466/CA/NCI NIH HHS/United States